Plasticity of mesenchymal stem cells in immunomodulation: Pathological and therapeutic implications

Nature Immunology

Volumn 15, Issue 11, 2014, Pages 1009-1016

  Wang, Ying ^a   Chen, Xiaodong ^a   Cao, Wei ^a   Shi, Yufang ^a,b,c  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b CHILD HEALTH INSTITUTE OF NEW JERSEY   (United States)

^c MEDICAL COLLEGE OF SOOCHOW UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CXCR3; CYCLOSPORIN A; DEXAMETHASONE; EPIDERMAL GROWTH FACTOR; FIBROBLAST GROWTH FACTOR; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 10; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 6; MONOCYTE CHEMOTACTIC PROTEIN 1; PLATELET DERIVED GROWTH FACTOR; PROSTAGLANDIN E2; SCATTER FACTOR; SOMATOMEDIN; STROMAL CELL DERIVED FACTOR 1; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 4; TRANSFORMING GROWTH FACTOR BETA; VASCULOTROPIN;

ADAPTIVE IMMUNITY; ANGIOGENESIS; APOPTOSIS; BLOOD VESSEL; CELL DIFFERENTIATION; CHEMOTAXIS; ENDOTHELIUM CELL; FIBROBLAST; HUMAN; IMMUNOMODULATION; IMMUNOREGULATION; INFLAMMATION; LYMPHOCYTE PROLIFERATION; MESENCHYMAL STEM CELL; NATURAL KILLER CELL; NONHUMAN; PATHOGENESIS; PLASTICITY; REVIEW; T LYMPHOCYTE; THERAPY EFFECT; TISSUE REGENERATION; CELL PROLIFERATION; IMMUNOLOGY; IMMUNOSUPPRESSIVE TREATMENT; MESENCHYMAL STROMA CELL; PHYSIOLOGY; REGENERATION; WOUND HEALING;

CELL DIFFERENTIATION; CELL PROLIFERATION; HUMANS; IMMUNOSUPPRESSION; INFLAMMATION; MESENCHYMAL STROMAL CELLS; REGENERATION; T-LYMPHOCYTES; WOUND HEALING;

EID: 84908132425     PISSN: 15292908     EISSN: 15292916     Source Type: Journal    
DOI: 10.1038/ni.3002     Document Type: Review

References (86)

1. Le Blanc K. & Mougiakakos D. Multipotent mesenchymal stromal cells and the innate immune system. Nat. Rev. Immunol. 12, 383-396 (2012).
2. Prockop D.J. & Oh J.Y. Mesenchymal stem/stromal cells (MSCs): role as guardians of inflammation. Mol. Ther. 20, 14-20 (2012).
3. Uccelli A., Moretta L. & Pistoia V. Mesenchymal stem cells in health and disease. Nat. Rev. Immunol. 8, 726-736 (2008).
4. Ren G. et al. Mesenchymal stem cell-mediated immunosuppression occurs via concerted action of chemokines and nitric oxide. Cell Stem Cell 2, 141-150 (2 008). Demonstrated that the immunosuppressive function of MSCs is not constitutive but is instead ' licensed' by inflammation.
5. Agata K. Regeneration and gene regulation in planarians. Curr. Opin. Genet. Dev. 13, 492-496 (2003).
6. Wagers A.J. & Weissman I.L. Plasticity of adult stem cells. Cell 116, 639-648 (2004).
7. Friedenstein A.J., Chailakhjan R.K. & L alykina K.S. The development of fibroblast colonies in monolayer cultures of guinea-pig bone marrow and spleen cells. Cell Tissue Kinet. 3, 393-403 (1970).
8. Bianco P. et al. The meaning, the sense and the significance: translating the science of mesenchymal stem cells into medicine. Nat. Med. 19, 35-42 (2013).
9. Caplan A.I. Mesenchymal stem cells. J. Orthop. Res. 9, 641-650 (1991).
10. Pittenger M.F. et al. Multilineage potential of adult human mesenchymal stem cells. Science 284, 143-147 (1999).
11. Jiang Y. et al. Pluripotency of mesenchymal stem cells derived from adult marrow. Nature 418, 41-49 (2002).
12. Bianco P., Robey P.G. & Simmons P.J. Mesenchymal stem cells: revisiting history, concepts, and assays. Cell Stem Cell 2, 313-319 (2008).
13. Keating A. Mesenchymal st romal cells: new directions. Cell Stem Cell 10, 709-716 (2012).
14. Horwitz E.M. et al. Clarification of the nomenclature for MSC: The International Society for Cellular Therapy position statement. Cytotherapy 7, 393-395 (2005).
15. Roberts E.W. et al. Depletion of stromal cells expressing fibroblast activation protein-alpha from skeletal muscle and bone marrow results in cachexia and anemia. J. Exp. Med. 210, 1137-1151 (2013).
16. Zhao H. et al. Secretion of shh by a neurovascular bundle niche supports mesenchymal stem cell homeostasis in the adult mouse incisor. Cell Stem Cell 14, 160-173 (2014).
17. Mé ndez-Ferrer S. et al. Mesenchymal and haematopoietic stem cells form a unique bone marrow niche. Nature 466, 829-834 (2010). Demonstrated that nestin-positive cells in bone marrow act functionally like MSCs and constitute the HSC niche.
18. Zhou B.O. Yue R. Murphy M.M. Peyer J.G. Morrison S.J. Leptin-receptor-expressing mesenchymal stromal cells re present the main source of bone formed by adult bone marrowi Cell Stem Cell 15 154-168 2014).
19. Sugiyama T., Kohara H., Noda M. & Nagasawa T. Maintenance of the hematopoietic s tem cell pool by CXCL12-CXCR4 chemokine signaling in bone marrow stromal cell niches. Immunity 25, 977-988 (2006).
20. Ren G. et al. Concise review: mesenchymal stem cells and translational medicine: emerging issues. Stem Cells Transl Med 1, 51-58 (2012).
21. Gao P. et al. Functional effects of TGF-?1 on mesenchymal stem cell mobilization in cockroach allergen-induced asthma. J. Immunol. 192, 4560-4570 (2014).
22. Qian H. et al. Bone marrow mesenchymal stem cells ameliorate rat acute renal failure by differentiation into renal tubular epithelial-like cells. Int. J. Mol. Med. 22, 325-332 (2008).
23. Cho K.A. et al. Mesenchymal stem cells showed the highest potential for the regeneration of injured liver tissue compared with other subpopulations of the bone marrow. Cell Biol. Int. 33, 772-777 (2009).
24. Han F. et al. Contribution of murine bone marrow mesenchymal stem cells to pancreas regeneration after partial pancreatectomy in mice. Cell Biol. Int. 36, 823-831 (2012).
25. Rose R.A. et al. Bone marrow-derived mesenchymal stromal cells express cardiac-specific markers, retain the stromal phenotype, and do not become functional cardiomyocytes in vitro. Stem Cells 26, 2884-2892 (2008).
26. Prockop D.J., Kota D.J., Bazhanov N. & Reger R.L. Evolving paradigms for repair of tissues by adult stem/progenitor cells (MSCs). J. Cell. Mol. Med. 14, 2190-2199 (2010).
27. von Bahr L. et al. Analysis of tissues following mesenchymal stromal cell therapy in humans indicates limited long-term engraftment and no ectopic tissue formation. Stem Cells 30, 1575-1578 (2012).
28. Tö gel F. et al. Administered mesenchymal stem cells protect against ischemic acute renal failure through differentiation-independent mechanisms. Am. J. Physiol. Renal Physiol. 289, F31-F42 (2005).
29. Sakaida I. et al. Transplantation of bone marrow cells reduces CCl4-induced liver fibrosis in mice. Hepatology 40, 1304-1311 (2004).
30. Lee R.H. et al. Intravenous hMSCs improve my ocardial infarction in mice because cells embolized in lung are activated to secrete the anti-inflammatory protein TSG-6. Cell Stem Cell 5, 54-63 (2009) Showed that intravenous infusion of human MSCs improves myocardial infarction in mice via TSG6 and that TSG6 alone is sufficient to provide the therapeutic effect.
31. Bai L. et al. Hepatocyte growth factor mediates mesenchymal stem cell-induced recovery in multiple sclerosis models. Nat. Neurosci. 15, 862-870 (2012).
32. Wolf D. et al. Regenerative capacity of intravenous autologous, allogeneic and human mesenchymal stem cells in the infarcted pig myocardium-complicated by myocardial tumor formation . Scand. Cardiovasc. J. 43, 39-45 (2009).
33. Ma S. et al. Immunobiology of mesenchymal stem cells. Cell Death Differ. 21, 216-225 (2014).
34. Ranganath S. H., Levy O., Inamdar M.S. & Karp J.M. Harnessing the mesenchymal stem cell secretome for the treatment of cardiovascular disease. Cell Stem Cell 10, 244-258 (2012).
35. Di Nicola, M . et al. Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood 99, 3838-3843 (2002).
36. Bartholomew A. et al. Mesenchy mal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo. Exp. Hematol. 30, 42-48 (2002).
37. McIntosh K.R., Mosca J.D. & Klyushnenkova E.N. Mesenchymal ste m cells for prevention and treatment of immune responses in transplantation. WO Patent 1999047163 A2, http://www.google.com/patents/WO1999047163A2?cl=en (1998).
38. Shi Y. et al. How mesenchymal stem cells interact with tissue immune responses. Trends Immunol. 33, 136-143 (2012).
39. Bernardo M.E. Fibbe W.E. Mesenchymal stromal cells: sensors and switchers of inflammation Cell Stem Cell 13 392-402 2013).
40. Luz-Crawford P. et al. Mesenchymal stem cells generate a CD4+CD25+Foxp3+ regulatory T cell population during the differentiation process of Th1 and Th17 cells. Stem Cell Res. Ther. 4, 65 (2013).
41. Deng Y. et al. Umbilical cord-derived mesenchymal stem cells instruct dendritic cells to acquire tolerogenic phenotypes through the IL-6-mediated upregulation of SOCS1. Stem Cells Dev. 23, 2080-2092 (2014).
42. Akiyama K. et al. Mesenchymal-stem-cell-induced immunoregulation involves FAS-ligand-/FAS-mediated T cell apoptosis. Cell Stem Cell 10, 544-555 (2012).
43. Németh K. et al. Bone marrow stromal cells attenuate sepsis via prostaglandin E2-dependent reprogramming of host macrophages to increase their interleukin-10 production. Nat. Med. 15, 42-49 (2009).
44. Abumaree M.H. et al. Human placental mesenchymal stem cells (pMSCs) play a role as immune suppressive cells by shifting macrophage differentiation from inflammatory M1 to anti-inflammatory M2 macrophages. Stem Cell Rev. 9, 620-641 (2013).
45. Spaggiari G.M., Capobianco A., Becchetti S., Mingari M.C. & Moretta L. Mesenchymal stem cell-natural killer cell interactions: evidence that activated NK cells are capable of killing MSCs, wher eas MSCs can inhibit IL-2-induced NK-cell proliferation. Blood 107, 1484-1490 (2006).
46. Spaggiari G.M. et al. Mesenchymal stem cells inhibit natural killer-cell proliferation, cytotoxicity, and cytoki ne production: role of indoleamine 2,3-dioxygenase and prostaglandin E2. Blood 111, 1327-1333 (2008).
47. Nemeth K. et al. Bone marrow stromal cells use TGF-? to suppress allergic responses in a mouse model of ragweed-induced asthma. Proc. Natl. Acad. Sci. USA 107, 5652-5657 (2010).
48. DelaRosa O. et al. Requirement of IFN-gamma-mediated indoleamine 2,3-dioxygenase expression in the modulation of l ymphocyte proliferation by human adipose-derived stem cells. Tissue Eng. Part A 15, 2795-2806 (2009).
49. Ortiz L.A. et al. Interleukin 1 receptor antagonist mediates the antiinflammatory and antifibrot ic effect of mesenchymal stem cells during lung injury. Proc. Natl. Acad. Sci. USA 104, 11002-11007 (2007).
50. Spaggiari G.M., Abdelrazik H., Becchetti F. & Moretta L. MSCs inhibit monocyte-d erived DC maturation and function by selectively interfering with the generation of immature DCs: central role of MSC-derived prostaglandin E2. Blood 113, 6576-6583 (2009).
51. Rafei M. et al. Mesenchymal stromal cells ameliorate experimental autoimmune encephalomyelitis by inhibiting CD4 Th17 T cells in a CC chemokine ligand 2-dependent manner. J. Immunol. 182, 5994-6002 (2009).
52. Krampera M. et al. Role for interferon-? in the immunomodulatory activity of human bone marrow mesenchymal stem cells. Stem Cells 24, 386-398 (2006).
53. Gieseke F. et a l. Human multipotent mesenchymal stromal cells inhibit proliferation of PBMCs independently of IFN?R1 signaling and IDO expression. Blood 110, 2197-2200 (2007).
54. Ren G. et al. Species variation in the mechanisms of mesenchymal stem cell-mediated immunosuppression. Stem Cells 27, 1954-1962 (2009).
55. Su J. et al. Phylogenetic distin ction of iNOS and IDO function in mesenchymal stem cell-mediated immunosuppression in mammalian species. Cell Death Differ. 21, 388-396 (2014).
56. Ling W. et al. Mesenchymal stem cells use IDO to regulate immunity in tumor microenvironment. Cancer Res. 74, 1576-1587 (2014).
57. Waterman R.S., Tomchuck S.L., Henkle S.L. & Betancourt A.M. A new mesenchymal stem cell (MSC) p aradigm: polarization into a pro-inflammatory MSC1 or an Immunosuppressive MSC2 phenotype. PLoS ONE 5, e10088 (2010)Proposed the concept of proinflammatory (MSC1) and anti-inflammatory (MSC2) phenotypes of MSCs and demonstrated difference s in their induction by TLR ligands.
58. Sudres M. et al. Bone marrow mesenchymal stem cells suppress lymphocyte proliferation in vitro but fail to prevent graft-versus-host disease in mice. J. Immunol. 176, 7761-7767 (2006).
59. Constantin G. et al. Adipose-derived mesenchymal stem cells ameliorate chronic experimental autoimmune encephalomyelitis. Stem Cells 27, 2624-2635 (2009).
60. Li W. et al. Mesenchymal stem cells: a double-edged sword in regulating immune responses. Cell Death Differ. 19, 1505-1513 (2012).
61. Renner P. et al. Mesenchymal stem cells require a sufficient, ongoing immune response to exert their immunosuppressive function. Transplant. Proc. 41, 2607-2611 (2009).
62. Chan J.L. et al. Antigen-presenting property of mesenchymal stem cells occurs during a narrow window at low levels of interferon-?. Blood 107, 4817-4824 (2006).
63. Franç ois M. et al. Mesenchymal stromal cells cross-present soluble exogenous antigens as part of their antigen-presenting cell properties. Blood 114, 2632-2638 (2009).
64. Mills K.H. TLR-dependent T cell activation in autoimmunity. Nat. Rev. Immunol. 11, 807-822 (2011).
65. Han X. et al. Interleukin-17 enhances immunosuppression by mesenchymal stem cells. Cell Death Differ. doi:10.1038/cdd.2014.85 (2014).
66. Li M.O. & Flavell R.A. Contextual regulation of inflammation: a duet by transforming growth factor-? and interleukin-10. Immunity 28, 468-476 (2008).
67. Li Z., Kupcsik L., Yao S.J., Alini M. & Stoddart M.J. Mechanical load modulates ch ondrogenesis of human mesenchymal stem cells through the TGF-? pathway. J. Cell. Mol. Med. 14, 1338-1346 (2010).
68. Crane J.L. & Cao X. Bone marrow mesenchymal stem cells and TGF-beta signaling in bone remodeling. J. Clin. Invest. 124, 466-472 (2014).
69. Xu C. et al. TGF-? promot es immune responses in the presence of mesenchymal stem cells. J. Immunol. 192, 103-109 (2014). Demonstrated that MSC-mediated immunosuppression of T cells can be reversed by TGF-b, a well-known immunosuppressive cytokine.
70. Raicevic G. et al. Inflammation modifies the pattern and the function of Toll-like receptors expressed by human mesenchymal stromal cells. Hum. Immunol. 71, 235-244 (2010).
71. I noue S. et al. Immunomodulatory effects of mesenchymal stem cells in a rat organ transplant model. Transplantation 81, 1589-1595 (2006). Showed that concurrent administration of MSCs with a low dose of cyclosporin A accelera tes allograft rejection.
72. Chen X. et al. The interaction between mesenchymal stem cells and steroids during inflammation. Cell Death Dis 5, e1009 (2014).
73. Burr S.P., Dazzi F. & Garden O.A. Mesenchymal stromal cells and regulatory T cells: the Yin and Yang of peripheral tolerance? Immunol. Cell Biol. 91, 12-18 (2013).
74. Le Blanc K. et al. Treatment o f severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet 363, 1439-1441 (2004). First report of a clinical application of MSCs in treating acute steroid-resistant GvHD.
75. Hare J.M. et al. Comparison of allogeneic vs autologous bone marrow-derived mesenchymal stem cells delivered by transendocardial injection in patients with ischemic cardiomyopathy: the POSEIDON randomized trial. J. Am. Med. Assoc. 3 08, 2369-2379 (2012).
76. Zhang Z. et al. Human umbilical cord mesenchymal stem cells improve liver function and ascites in decompensated liver cirrhosis patients. J. Gastroenterol. Hepatol. 27 (suppl. 2), 112-120 (2012).
77. Le Blanc K. et al. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet 371, 1579-1586 (2008).
78. Sun L. et al. Umbilical cord mesenchymal stem cell transplantation in severe and refractory systemic lupus erythematosus. Arthritis Rheum. 62, 2467-2475 (2010).
79. Tyndall A. & van Laar J.M. Stem cells in the treatment of inflammatory arthritis. Best Pract. Res. Clin. Rheumatol. 24, 565-574 (2010).
80. Krampera M., Galipeau J., Shi Y., Tarte K. & Sensebe L. Immunological characterization of multipotent mesenchymal stromal cells-The International Society for Cellular Therapy (ISCT) working proposal. C ytotherapy 15, 1054-1061 (2013).
81. Krampera M. Mesenchymal stromal cell 'licensing ': a multistep process. Leukemia 25, 1408-1414 (2011).
82. Dalal J. Gandy K. Domen J Role of mesenchymal stem cell therapy in Crohn's disease Pediatr. Res. 71 445-451 2012).
83. Baker M. Stem-cell drug fails crucial trials. in Nature http://www.nature.com/news/2009/090909/full/news.2009.894.html (2009). Revealed that Prochymal (an MSC-based product) performed no more effectively than a placebo in a phase III clinical trial targeting GvHD; here, Prochym al was used together with steroid and that treatment was compared with steroid alone.
84. Duijvestein M. et al. Pretreatment with interferon-? enhances the therapeutic activity of mesenchymal stromal cells in animal models of colitis. Stem Cells 29, 1549-1558 (2011).
85. Luo Y. et al. Pretreating mesenchymal stem cells with interleukin-1? and transforming growth factor-? synergistically increases vascular endothelia l growth factor production and improves mesenchymal stem cell-mediated myocardial protection after acute ischemia. Surgery 151, 353-363 (2012).
86. Polchert D. et al. IFN-? activation of mesenchymal stem cells for treatment and prevention of graft versus host disease. Eur. J. Immunol. 38, 1745-1755 (2008).